H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 40.5 HKD 0.55% Market Closed
Market Cap: 245.2B HKD

Hansoh Pharmaceutical Group Company Ltd
Interest Income Expense

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Hansoh Pharmaceutical Group Company Ltd
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Interest Income Expense
¥1.1B
CAGR 3-Years
34%
CAGR 5-Years
32%
CAGR 10-Years
N/A
C
CSPC Pharmaceutical Group Ltd
HKEX:1093
Interest Income Expense
-¥90.2m
CAGR 3-Years
-19%
CAGR 5-Years
N/A
CAGR 10-Years
-9%
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Interest Income Expense
¥391.3m
CAGR 3-Years
51%
CAGR 5-Years
28%
CAGR 10-Years
17%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Interest Income Expense
¥649.7m
CAGR 3-Years
-2%
CAGR 5-Years
3%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Interest Income Expense
¥1.3B
CAGR 3-Years
89%
CAGR 5-Years
-3%
CAGR 10-Years
35%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Interest Income Expense
¥258.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Nestled in the heart of China's burgeoning pharmaceutical industry, Hansoh Pharmaceutical Group Company Ltd. stands as a beacon of innovation and resilience. Founded in 1995, Hansoh has carved a niche for itself by focusing on the development, manufacturing, and distribution of a diverse portfolio of drugs. The company has garnered attention by zeroing in on therapeutic areas such as oncology, central nervous system disorders, anti-infectives, and diabetes, aiming to address the pressing needs of a growing patient population. This targeted strategy has not only positioned Hansoh as a formidable player in China's pharmaceutical landscape but also allowed it to compete on a global scale through its commitment to high-quality and affordable healthcare solutions. Hansoh's business model revolves around two core components: research and development (R&D) and strategic distribution. The company has invested heavily in R&D, maintaining an extensive pipeline of innovative drugs that promise to bolster its revenue streams. By focusing on a mix of generic and proprietary medications, Hansoh capitalizes on both established market demands and emerging medical needs. Additionally, its robust distribution network ensures that its products reach a broad array of hospitals and pharmacies, both within China and beyond. This dual approach of scientific advancement paired with efficient delivery mechanisms underpins Hansoh's business success, allowing it to generate steady revenues while paving the way for future growth in international markets.

Intrinsic Value
25.79 HKD
Overvaluation 36%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense?
Interest Income Expense
1.1B CNY

Based on the financial report for Jun 30, 2025, Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense amounts to 1.1B CNY.

What is Hansoh Pharmaceutical Group Company Ltd's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
32%

Over the last year, the Interest Income Expense growth was -14%. The average annual Interest Income Expense growth rates for Hansoh Pharmaceutical Group Company Ltd have been 34% over the past three years , 32% over the past five years .

Back to Top